Arbutus Biopharma Corp 8-K

What Happened Arbutus Biopharma Corporation (ABUS) filed a Form 8-K on April 15, 2026 (Item 8.01) announcing that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to imdusiran for the treatment of chronic hepatitis B. The company issued a press release on the same date, which is attached to the filing as Exhibit 99.1 and incorporated by reference.

Key Details

• FDA granted Fast Track designation for imdusiran for chronic hepatitis B (announcement dated April 15, 2026).
• The Fast Track program is intended to facilitate development and expedite review of therapies for serious conditions with unmet medical need.
• The press release is filed as Exhibit 99.1 to the Form 8-K (Item 9.01(d)).
• The filing is signed by Chief Financial Officer Tuan Nguyen on behalf of Arbutus Biopharma.

Why It Matters Fast Track designation is an early regulatory recognition that can enable more frequent interactions with the FDA and potential expedited review pathways, which may help accelerate development timelines for imdusiran. For investors, this is a regulatory progress milestone for Arbutus’s HBV program but does not indicate approval, clinical results, or guaranteed commercial success. The filing contains no new financial results or operational changes beyond the press release announcement.